News
News & Updates
News & Updates
-
Tetra Biotech Launches Special Promotion to Celebrate the Korean Debut of YURI RPM 2.0
To celebrate the official Korean launch of YURI GmbH’s RPM 2.0 microgravity simulator, Tetra Biotech is offering a special introductory promotion.
The first two units ordered will be supplied at 25% off the list price. The offer runs until December 31, 2026, and will close early once bothunits are sold.
RPM 2.0 randomly rotates samples to recreate microgravity on the groundand is used by more than 60 research groups worldwide, including NASA and ESA.
It supports a wide range of research, fr|om 3D cell culture and organoids totissue engineering and space biology.
Along with the instrument, we provide scientific support incollaboration with the manufacturer, including installation, operator trainingand experimental design consultation.
Labs planning microgravity research won’twant to miss this opportunity.
Product: YURI RPM 2.0 (Random Positioning Machine)
Offer: 25% off list price
Availability: Limited to the first 2 units
Period: Through December 31, 2026 (ends early when sold out)
Contact: info@tetrabiotech.com / +82-42-489-8891
Available to customers in Korea only.
We look forward to hearing fr|om researchers interested in YURI RPM 2.0.
- 2026.10.01
-
Tetra Biotech Concluded Official Partnership with Germany’s YURI GmbH
Tetra Biotech has entered into a partnership
with YURI GmbH, a German space biotech company, to become its officialdistributor in Korea. Under the agreement,
Tetra Biotech will supply YURI’s microgravity simulation systems — the RPM 2.0 (Random Positioning Machine) andthe Clinostat — to cell biology researchers across Korea.
RPM 2.0 continuously and randomly changes theorientation of samples to create a space-like microgravity environment on Earth.
First developed by Airbus more than 20 years ago, the technology was acquired by YURI in 2023, which has continued its development and supply eversince.
A proven rotation-path algorithm allows users to set conditions ranging fr|om microgravity (10⁻³ g) to Moon- and Mars-level partial gravity(up to 0.9 g), and its compact footprint means it runs directly inside astandard incubator.
With an extensive track record, RPM 2.0 is recognized as the global goldstandard in its field. It is used by more than 60 research groups worldwide,including NASA and the European Space Agency (ESA), and has supported both the preparation of International Space Station (ISS) experiments and post-flightcomparative analysis. Applications span cell biology, cancer research, 3D cellculture and organoids, tissue engineering, and microbial and plant research.The manufacturer, YURI, is a leader in space biotech with more than 30 years ofexperience and 11 ISS missions to its name.
Going beyond instrument supply, Tetra Biotech will work closely with the manufacturer to provide expert scientific support, including installation, training, experimental design consultation and technical documentation. Ourgoal is to help Korean researchers get the most out of a world-classmicrogravity research environment.
- 2026.08.03
-
Tetra Biotech Selected for Korea’s 2026 Startup-Centered University Program
Tetra Biotech has been selected as a Daejeon-region company for the 2026 Startup-Centered University Program, led by Hannam University and run by Korea’s Ministry of SMEs and Startups (MSS) and the Korea Institute of Startup & Entrepreneurship Development (KISED).
One of the Korean government’s flagship startup initiatives, the program has regional lead universities identify promising early-stage startups and provide them with commercialization funding and tailored growth programs, linking university infrastructure with regional innovation resources to strengthen local startup ecosystems.
The selection is an independent endorsement of our technology and growth potential.
During the evaluation, Tetra Biotech presented its commercialization plan for TetraZyme™, an enzyme enhanced through Structure-Guided Mutation Engineering (SGME),
along with the PCR master mixes and molecular diagnostic kits built on it.
Evaluators particularly highlighted our ability to develop and manufacture everything fr|om the core enzyme technology to finished products, as well as our global market strategy.
With this support, we will accelerate further enhancement of our SGME enzymes, the development of new detection kits, the build-out of our quality and certification systems, and the expansion of our overseas sales channels.
We will also work closely with Hannam University, the lead institution, to deliver tangible commercial results.
- 2026.06.10
-
Tetra Biotech Moves into the Hanbat National University Business Incubation Center
Having passed the final selection review, Tetra Biotech moved into the Business Incubation Center of the Hanbat National University Industry-Academic Cooperation Foundation,
located on the Daedeok Industry-Academia Convergence Campus, on November 1, 2025.
Tetra Biotech owns the TetraZyme™ platform, which enhances PCR enzyme performance through Structure-Guided Mutation Engineering (SGME).
In thereview, we presented a staged plan to commercialize this core enzymetechnology, first as PCR master mixes and then as molecular diagnostic kits. The plan was recognized for both its technical merit and its market potential.
Located within Daedeok Innopolis, Korea’s leading R&D hub, our newhome gives us a stable base for ongoing research and production.
We will makefull use of the center’s incubation programs — including expert mentoring,investor connections and its industry-academia-research network — as we preparefor our next stage of growth.
- 2025.11.01